ASCO 2021: Dr. Matthew Davids on Acalabrutinib vs. Ibrutinib for Chronic Lymphocytic Leukemia (CLL) At the annual meeting of the American Society of Clinical Oncology (ASCO) 2021, our own Dr. Brian Koffman interviewed Dr.... October 8, 20212021 ConferencesBy Brad Hedrick
ASCO 2021 Top Pick #12: Acalabrutinib ± Obinutuzumab Versus Obinutuzumab + Chlorambucil in Treatment-Naïve Chronic Lymphocytic Leukemia: ELEVATE-TN Four-Year Follow Up While hardly groundbreaking, the four-year follow-up data of the ELEVATE-TN trial affirms our confidence that acalabrutinib is a strong choice... October 4, 20212021 ConferencesBy Brad Hedrick
EHA 2021 Top Pick #11: Fixed-Duration Ibrutinib and Venetoclax (I+V) Versus Chlorambucil Plus Obinutuzumab (Clb+O) for First Line (1L) Chronic Lymphocytic Leukemia (CLL): Primary Analysis of the Phase 3 GLOW Study Ibrutinib and Venetoclax have as we like to say at the CLL Society orthogonal or complementary mechanisms of action. Ibrutinib... October 4, 20212021 ConferencesBy Brad Hedrick
ASCO 2021 Top Pick #10: Survival trends in chronic lymphocytic leukemia in the era of oral targeted therapies in the United States: SEER database analyses (1985 to 2017) In this paper presented at ASCO 2021 by Alrawashdh et al, we learn about historical survival trends for CLL patients... October 4, 20212021 ConferencesBy Brad Hedrick
EHA 2021 Top Pick #9: Ibrutinib Treatment in the First Line Setting for Patients with Chronic Lymphocytic Leukemia. Up to 7 Years of Follow-Up in the RESONATE-2 Study Dr. Paolo Ghia, at the European Hematology Association (EHA) 2021 virtual annual meeting, presented the results of seven years of... October 4, 20212021 ConferencesBy Brad Hedrick
ASCO 2021 Top Pick #8: First-in-human study of lisaftoclax (APG-2575), a novel BCL-2 inhibitor (BCL-2i), in patients with relapsed/refractory (R/R) CLL and other hematologic malignancies In this ASCO 2021 abstract by Ailawadhi from Mayo and others, we learn of the first in human trial of... October 4, 20212021 ConferencesBy Brad Hedrick
EHA 2021 Top Pick #7: Long Term Results of a Phase I/Ib Study of Ibrutinib in Combination with Umbralisib in Patients with Relapsed/Refractory (R/R) CLL (Chronic Lymphocytic Leukemia) or MCL (Mantle Cell Lymphoma) Dr. Matt Davids of Dana Farber presented this abstract at the 2021 European Hematology Association Virtual Congress, (EHA 2021) that... October 4, 20212021 ConferencesBy Brad Hedrick
ASCO 2021 Top Pick #6: Fixed-duration (FD) First-Line Treatment (Tx) with Ibrutinib (I) Plus Venetoclax (V) for Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL): Primary Analysis of the FD Cohort of the Phase 2 CAPTIVATE study. The CAPTIVATE study data has been highly anticipated. At ASH 2020, we got important results. Dr. Wierda presented the results... October 4, 20212021 ConferencesBy Brad Hedrick
EHA 2021 Top Pick #5: Pirtobrutinib (Loxo-305), A Next Generation, Highly Selective, Non-Covalent BTK Inhibitor in Previously Treated CLL/SLL: Results from the Phase 1/2 Bruin Study Dr. Lindsey Roeker of MSKCC, NYC, NY presented results at 2021 European Hematology Association Virtual Congress, (EHA 2021).... October 4, 20212021 ConferencesBy Brad Hedrick
EHA 2021 Top Pick #4: First Interim Analysis of ALPINE Study: Results of a Phase 3 Randomized Study of Zanubrutinib vs Ibrutinib in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma This was accepted as a late breaking abstract at the 2021 European Hematology Association Virtual Congress, (EHA 2021), reflecting its... October 4, 20212021 ConferencesBy Brad Hedrick
